Williams S C, Oehninger S, Gibbons W E, Van Cleave W C, Muasher S J
The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23517, USA.
Fertil Steril. 2001 Dec;76(6):1140-3. doi: 10.1016/s0015-0282(01)02914-4.
To compare IVF outcome between two protocols for luteal phase supplementation, one beginning on day 3 after oocyte retrieval and the other beginning on day 6 after retrieval.
Prospective, randomized study.
University-based assisted reproductive technology center.
PATIENT(S): One hundred twenty-six consecutive patients undergoing IVF between January and July 2000.
INTERVENTION(S): Patients were randomized to begin luteal phase support using vaginal progesterone beginning either on day 3 after oocyte retrieval or on day 6 after oocyte retrieval.
MAIN OUTCOME MEASURE(S): Clinical pregnancy rates and implantation rates.
RESULT(S): All patients randomized underwent transfer. There were no differences in age, oocytes retrieved, or embryos transferred between the two groups. Those patients receiving luteal phase support with progesterone beginning on day 6 after retrieval had a significantly lower clinical pregnancy rate per transfer compared with those beginning support on day 3 after retrieval (44.8% vs. 61.0%, respectively). This difference in pregnancy rates was greater in those patients undergoing a luteal gonadotropin releasing hormone (GnRH) agonist down-regulation protocol (47.5% vs. 71.4%, day 6 vs. day 3, respectively). Beginning support on day 6 also significantly decreased implantation rates in the GnRH agonist group (21.0% vs. 34.0%, day 6 vs. day 3, respectively).
CONCLUSION(S): Pregnancy rates are significantly decreased by initiating luteal-phase progesterone supplementation on day 6 after oocyte retrieval during in vitro fertilization cycles.
比较两种黄体期补充方案的体外受精结局,一种在取卵后第3天开始,另一种在取卵后第6天开始。
前瞻性随机研究。
大学附属辅助生殖技术中心。
2000年1月至7月期间连续126例行体外受精的患者。
患者被随机分为两组,分别在取卵后第3天或第6天开始使用阴道黄体酮进行黄体期支持。
临床妊娠率和着床率。
所有随机分组的患者均接受了胚胎移植。两组患者在年龄、取卵数或移植胚胎数方面无差异。与在取卵后第3天开始黄体期支持的患者相比,在取卵后第6天开始使用黄体酮进行黄体期支持的患者每次移植的临床妊娠率显著降低(分别为44.8%和61.0%)。在接受黄体期促性腺激素释放激素(GnRH)激动剂降调节方案的患者中,妊娠率的差异更大(第6天和第3天分别为47.5%和71.4%)。在GnRH激动剂组中,在第6天开始支持也显著降低了着床率(第6天和第3天分别为21.0%和34.0%)。
在体外受精周期中,取卵后第6天开始黄体期黄体酮补充会显著降低妊娠率。